This Allocord market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as an increase in the prevalence of genetic disorders, greater awareness of cord blood transplantation, government support for stem cell therapies, improvements in medical infrastructure, and a rise in the incidence of severe combined immunodeficiency (SCID).
Market growth during the forecast period is expected to be driven by factors such as increased global healthcare access, rising demand for personalized medicine, expanding donor registries, improved transplant success rates, and growing awareness and education about cord blood banking. Key trends in the forecast period include the integration of artificial intelligence in stem cell matching, the expansion of public-private partnerships in stem cell research, the development of next-generation cryopreservation solutions, collaboration between healthcare providers and stem cell banks, and the adoption of personalized treatment plans.
The increasing prevalence of chronic diseases is expected to drive the growth of the allocord market. Chronic diseases, which are long-lasting conditions that typically progress slowly and require continuous management, are becoming more common due to unhealthy lifestyles, aging populations, socioeconomic disparities, and urbanization affecting access to healthcare. Allocord helps address this rising prevalence by offering cord blood banking services, granting access to stem cell-based regenerative therapies and innovative treatment options for managing these conditions. For example, in April 2024, Allergy UK reported that more than 21 million people in the UK suffer from allergies, which became the most commonly reported chronic health condition in 2022. Projections indicate that by 2026, half of Europe’s population will experience at least one allergy. Therefore, the growing prevalence of chronic diseases is driving the expansion of the allocord market.
The increasing focus on personalized medicine is expected to further boost the allocord market. Personalized medicine tailors medical treatments and prevention strategies based on individual genetic, environmental, and lifestyle factors. The growing interest in personalized medicine is driven by advancements in genomics, precision diagnostics, and the increasing demand for more effective, individualized healthcare solutions. Allocord supports this trend by providing cord blood banking services that facilitate access to stem cells for customized regenerative therapies and targeted treatments. For instance, in February 2024, the Personalized Medicine Coalition reported that the USFDA approved 16 new personalized treatments for rare diseases in 2023, a notable increase from 6 in 2022. Thus, the rising interest in personalized medicine is fueling the growth of the allocord market.
Rising healthcare spending is expected to contribute to the growth of the allocord market. Healthcare expenditure refers to the total amount spent on health services and related activities over a specified period. The increase in healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, technological advancements, and the impact of the COVID-19 pandemic. Allocord benefits from this increase in spending by providing cord blood banking services that enable advanced regenerative therapies, offering innovative and cost-effective treatment options. For example, in September 2024, Cross River Therapy reported that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021, and spending is expected to rise to $605-$635 billion by 2025. Therefore, the rise in healthcare expenditure is expected to drive the growth of the allocord market.
The key company operating in the allocord market is SSM Cardinal Glennon Children's Medical Center.
North America was the largest region in the allocord market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in allocord report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allocord market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Allocord is a therapeutic product designed to treat severe combined immunodeficiency (SCID) and other rare genetic disorders. It provides essential enzyme replacement therapy, helping to manage these conditions by replenishing the enzyme necessary for proper immune system function.
The primary formulations of allocord are injectable suspension and cryopreserved units. The injectable suspension is a liquid-based cord blood product intended for direct administration to patients who require regenerative or therapeutic treatments. It is used for conditions such as hematopoietic disorders, immunologic disorders, inherited disorders, and acquired disorders. Allocord is used by adult, pediatric, and geriatric patients and is distributed through various channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies.
The allocord market research report is one of a series of new reports that provides allocord market statistics, including allocord industry global market size, regional shares, competitors with a allocord market share, detailed allocord market segments, market trends and opportunities, and any further data you may need to thrive in the allocord industry. This allocord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The allocord market consists of sales of hematopoietic progenitor cell (HPC) products, cord blood injectable suspension, and cryopreserved cord blood units. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as an increase in the prevalence of genetic disorders, greater awareness of cord blood transplantation, government support for stem cell therapies, improvements in medical infrastructure, and a rise in the incidence of severe combined immunodeficiency (SCID).
Market growth during the forecast period is expected to be driven by factors such as increased global healthcare access, rising demand for personalized medicine, expanding donor registries, improved transplant success rates, and growing awareness and education about cord blood banking. Key trends in the forecast period include the integration of artificial intelligence in stem cell matching, the expansion of public-private partnerships in stem cell research, the development of next-generation cryopreservation solutions, collaboration between healthcare providers and stem cell banks, and the adoption of personalized treatment plans.
The increasing prevalence of chronic diseases is expected to drive the growth of the allocord market. Chronic diseases, which are long-lasting conditions that typically progress slowly and require continuous management, are becoming more common due to unhealthy lifestyles, aging populations, socioeconomic disparities, and urbanization affecting access to healthcare. Allocord helps address this rising prevalence by offering cord blood banking services, granting access to stem cell-based regenerative therapies and innovative treatment options for managing these conditions. For example, in April 2024, Allergy UK reported that more than 21 million people in the UK suffer from allergies, which became the most commonly reported chronic health condition in 2022. Projections indicate that by 2026, half of Europe’s population will experience at least one allergy. Therefore, the growing prevalence of chronic diseases is driving the expansion of the allocord market.
The increasing focus on personalized medicine is expected to further boost the allocord market. Personalized medicine tailors medical treatments and prevention strategies based on individual genetic, environmental, and lifestyle factors. The growing interest in personalized medicine is driven by advancements in genomics, precision diagnostics, and the increasing demand for more effective, individualized healthcare solutions. Allocord supports this trend by providing cord blood banking services that facilitate access to stem cells for customized regenerative therapies and targeted treatments. For instance, in February 2024, the Personalized Medicine Coalition reported that the USFDA approved 16 new personalized treatments for rare diseases in 2023, a notable increase from 6 in 2022. Thus, the rising interest in personalized medicine is fueling the growth of the allocord market.
Rising healthcare spending is expected to contribute to the growth of the allocord market. Healthcare expenditure refers to the total amount spent on health services and related activities over a specified period. The increase in healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, technological advancements, and the impact of the COVID-19 pandemic. Allocord benefits from this increase in spending by providing cord blood banking services that enable advanced regenerative therapies, offering innovative and cost-effective treatment options. For example, in September 2024, Cross River Therapy reported that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021, and spending is expected to rise to $605-$635 billion by 2025. Therefore, the rise in healthcare expenditure is expected to drive the growth of the allocord market.
The key company operating in the allocord market is SSM Cardinal Glennon Children's Medical Center.
North America was the largest region in the allocord market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in allocord report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allocord market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Allocord is a therapeutic product designed to treat severe combined immunodeficiency (SCID) and other rare genetic disorders. It provides essential enzyme replacement therapy, helping to manage these conditions by replenishing the enzyme necessary for proper immune system function.
The primary formulations of allocord are injectable suspension and cryopreserved units. The injectable suspension is a liquid-based cord blood product intended for direct administration to patients who require regenerative or therapeutic treatments. It is used for conditions such as hematopoietic disorders, immunologic disorders, inherited disorders, and acquired disorders. Allocord is used by adult, pediatric, and geriatric patients and is distributed through various channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies.
The allocord market research report is one of a series of new reports that provides allocord market statistics, including allocord industry global market size, regional shares, competitors with a allocord market share, detailed allocord market segments, market trends and opportunities, and any further data you may need to thrive in the allocord industry. This allocord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The allocord market consists of sales of hematopoietic progenitor cell (HPC) products, cord blood injectable suspension, and cryopreserved cord blood units. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Allocord Market Characteristics4. Allocord Market Trends and Strategies5. Allocord Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Allocord Pricing Analysis & Forecasts30. Global Allocord Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Allocord Market32. Recent Developments in the Allocord Market
3. Allocord Market Biologic Drug Characteristics
6. Global Allocord Growth Analysis and Strategic Analysis Framework
8. Allocord Market Segmentation
9. Global Allocord Epidemiology of Clinical Indications
10. Allocord Market Regional and Country Analysis
11. Asia-Pacific Allocord Market
12. China Allocord Market
13. India Allocord Market
14. Japan Allocord Market
15. Australia Allocord Market
16. South Korea Allocord Market
17. Western Europe Allocord Market
18. UK Allocord Market
19. Germany Allocord Market
20. France Allocord Market
21. Eastern Europe Allocord Market
22. North America Allocord Market
23. USA Allocord Market
24. Canada Allocord Market
25. South America Allocord Market
26. Middle East Allocord Market
27. Africa Allocord Market
28. Allocord Market Competitive Landscape and Company Profiles
29. Global Allocord Market Pipeline Analysis
33. Allocord Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Allocord Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on allocord market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for allocord? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The allocord market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Suspension; Cryopreserved Units2) by Clinical Indication: Hematopoietic Disorders; Immunologic Disorders; Inherited Disorders; Acquired Disorders
3) by End User: Adult Patients; Pediatric Patients; Geriatric Patients
4) by Distribution Channel: Hospitals and Clinics; Retail and Specialty Pharmacies
Key Companies Mentioned: SSM Cardinal Glennon Children's Medical Center
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- SSM Cardinal Glennon Children's Medical Center
